drug:cagrisema CagriSema underperforms in trial We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s
politics Medicare/Medicaid might pay for GLP1s again GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.
chemical:semaglutide Another GLP1 Generic launch: India's Dr Reddy's Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
company:hims Hims will sell generic Semaglutide in 2026 Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
company:novo-nordisk Novo Nordisk is introducing a higher dose of Wegovy Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
company:weight-watchers Novo's expanding collaboration with Weight Watchers Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
category:news A glowing endorsement of GLP1s by cardiologists Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
category:risks A new risk? Macular Degeneration We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.
drug:orforglipron Updates from MariTide & Orforglipron research MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
chemical:semaglutide After two months, Novo Nordisk and HIMS part ways Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
category:news Preserving muscle: GLP1s with Bimagrumab We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
company:novo-nordisk Novo Nordisk patent protections lapse in Canada Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
category:news A challenge to Eli Lilly's Tirzepatide patent Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
drug:eloralinitide Amylin, with and without GLP1: Eloralinitide We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
category:side-effects Ozempic is not likely to directly enlarge the male appendage. A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly Eli Lilly's big Summer 2025 update We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
category:news A new risk: Kidney Cancer New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
drug:retatrutide An update on Retatrutide (May 2025) We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
politics GLP1s and Tariffs, the story so far We take a look at the various movements in GLP1 policy by the Trump administration, so far.
drug:wegovy Wegovy in pill form is coming Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
drug:nimacimab Boosting Tirzepatide with Nimacimab Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.
company:eli-lilly Eli Lilly suing GLP1 compounders & related companies Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
company:pfizer Pfizer ends development of oral GLP1 Danuglipron Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
category:news Oral pill Orforglipron delivers stellar results in Phase 3 Trial Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!
politics Trump revokes planned Medicare/Medicaid coverage for GLP1s Trump administration revokes the planned Medicare Part D coverage for anti-obesity GLP1 drugs.
